OverviewSuggest Edit

Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
TypePublic
Founded2012
HQSan Carlos, US
Websiteallakos.com

Latest Updates

Employees (est.) (Feb 2019)51(+16%)
Share Price (May 2019)$44 (-1%)

Key People/Management at Allakos

Christopher Bebbington

Christopher Bebbington

Founder
Nenad Tomasevic

Nenad Tomasevic

Vice President of Research
Show more

Allakos Office Locations

Allakos has an office in San Carlos
San Carlos, US (HQ)
75 Shoreway Rd Suite A
Show all (1)

Allakos Financials and Metrics

Allakos Revenue

USD

Net income (FY, 2018)

(43.5m)

EBIT (FY, 2018)

(45.7m)

Market capitalization (22-May-2019)

1.9b

Closing stock price (22-May-2019)

44.0

Cash (30-Sep-2018)

51.6m
Allakos's current market capitalization is $1.9 b.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

2.4m3.7m12.4m

R&D expense

14.7m18.5m33.3m

Operating expense total

17.1m22.3m45.7m

EBIT

(17.1m)(22.3m)(45.7m)
Quarterly
USDQ2, 2018Q3, 2018

General and administrative expense

2.4m3.3m

R&D expense

7.1m8.7m

Operating expense total

9.5m12.0m

EBIT

(9.5m)(12.0m)
Annual
USDFY, 2016FY, 2017

Cash

13.4m85.2m

Prepaid Expenses

150.0k1.0m

Current Assets

13.6m86.2m

PP&E

333.0k445.0k
Quarterly
USDQ2, 2018Q3, 2018

Cash

19.3m51.6m

Current Assets

67.1m197.2m

PP&E

3.4m7.6m

Total Assets

74.2m205.8m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(17.1m)(23.6m)(43.5m)

Depreciation and Amortization

148.0k241.0k242.0k

Accounts Payable

(1.1m)510.0k76.0k

Cash From Operating Activities

(17.6m)(22.6m)(38.4m)
Quarterly
USDQ2, 2018Q3, 2018

Net Income

(17.9m)(29.0m)

Depreciation and Amortization

119.0k183.0k

Accounts Payable

(647.0k)915.0k

Cash From Operating Activities

(17.4m)(25.8m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Allakos News and Updates

Allakos Reports First Quarter 2019 Financial Results

REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019.

Allakos Blogs

Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights

Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights Content Import Thu, 03/14/2019 - 16:03 Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights March 14, 2019 at 4:01 PM EDT …

Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis

Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis Content Import Tue, 02/19/2019 - 08:13 Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis February 19, 2019 at 8:00 AM EST This release…

Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts

Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts Janice.Nispero… Mon, 02/11/2019 - 08:10 Allakos Announces Positive Phase 2 Results for AK002 in Patients w…

Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients

Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients Content Import Mon, 01/07/2019 - 08:14 Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients January 7, 2019 …

Allakos Announces Clinical Update and Third Quarter 2018 Financial Results

Allakos Announces Clinical Update and Third Quarter 2018 Financial Results Content Import Thu, 11/08/2018 - 16:04 Allakos Announces Clinical Update and Third Quarter 2018 Financial Results November 8, 2018 at 4:01 PM EST This release is a backfill from a News …

Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

SAN CARLOS, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced the presentation of two posters at the American College

Allakos Frequently Asked Questions

  • When was Allakos founded?

    Allakos was founded in 2012.

  • Who are Allakos key executives?

    Allakos's key executives are Christopher Bebbington and Nenad Tomasevic.

  • How many employees does Allakos have?

    Allakos has 51 employees.

  • Who are Allakos competitors?

    Competitors of Allakos include Sosei Heptares, CinCor Pharma and Seres Therapeutics.

  • Where is Allakos headquarters?

    Allakos headquarters is located at 75 Shoreway Rd Suite A, San Carlos.

  • Where are Allakos offices?

    Allakos has an office in San Carlos.

  • How many offices does Allakos have?

    Allakos has 1 office.